Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore

Emerging Infectious Diseases

Volumn 12, Issue 1, 2006, Pages 95-102

  Lee, Vernon J ^a,d   Kai, Hong Phua ^b   Chen, Mark I ^a   Chow, Angela ^c   Ma, Stefan ^c   Kee, Tai Goh ^c   Yee, Sin Leo ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MINISTRY OF HEALTH   (Singapore)

^d NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE INHIBITOR;

ARTICLE; CALCULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; INFLUENZA; MONTE CARLO METHOD; MORTALITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; SINGAPORE;

EID: 31344433106     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1201.050556     Document Type: Article

References (37)

1. Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21:1776-9.
2. Ng TP, Pwee TH, Niti M, Goh LG. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore. 2002;31:182-8.
3. Gust ID, Hampson AW, Lavanchy D. Planning for the next pandemic of influenza. Rev Med Virol. 2001;11:59-70.
4. van Genugten MLL, Heijnen MA, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis. 2003;9:531-8.
5. Muenning PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis. 2001;33:1879-85.
6. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-63.
7. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002;137:225-31.
8. Balicer RD, Huerta M, Davidovitch N, Grotto I. Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis. 2005;11:1280-2.
9. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet. 2000;355:1845-50.
10. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol. 2000;40:836-43.
11. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-72.
12. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336-43.
13. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659-71.
14. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health. 1987;77:712-6.
15. Ammon CE. Spanish flu epidemic in 1918 in Geneva, Switzerland. Euro Surveillance. 2002;7:190-2.
16. Key statistics. Singapore Department of Statistics. [cited 2005 May 3]. Available from http://www.singstat.gov.sg/
17. Tan CH, Emmanuel SC, Tan BY, Jacob E. Prevalence of diabetes and ethnic differences in cardiovascular risk factors. Diabetes Care. 1999;22:241-7.
18. Ng TP. Adult asthma prevalence, morbidity and mortality and their relationships with environmental and medical care factors in Singapore. Asian Pac J Allergy Immunol. 1999;17:127-35.
19. Heng DM, Lee J, Chew SK, Tan BY, Hughes K, Chia KS. Incidence of ischaemic heart disease and stroke in Chinese, Malays, and Indians in Singapore: Singapore Cardiovascular Cohort Study. Ann Acad Med Singapore. 2000;29:231-6.
20. Wang XS, Tan TN, Shek LP, Chng SY, Hia CP, Ong NB, et al. The prevalence of asthma and allergies in Singapore; data from two ISAAC surveys seven years apart. Arch Dis Child. 2004;89:423-6.
21. Emmanuel SC, Phua HP, Cheong PY. 2001 survey on primary medical care in Singapore. Singapore Med J. 2004;45:199-213.
22. Kadri ZN. An outbreak of "Hong Kong flu" in Singapore. Singapore Med J. 1970;11:30-2.
23. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18:64-76.
24. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7:1-182.
25. Haddix AC, Teutsh SM, Corso PS. Prevention effectiveness-a guide to decision analysis and economic evaluation. 2nd ed. New York: Oxford University Press; 2003.
26. Lee KH, Chin NK, Tan WC, Lim TK. Hospitalised low risk community-acquired pneumonia: outcome and potential for cost-savings. Ann Acad Med Singapore. 1999;28:389-91.
27. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24.
28. Woodall J, Rowson KEK, McDonald JC. Age and Asian influenza. BMJ. 1958;4:1316-8.
29. Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, et al. Oseltamivir Compassionate Use Program Group. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc. 2002;50:608-16.
30. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285: 748-54.
31. Doraisingham S, Goh KT, Ling AE, Yu M. Influenza surveillance in Singapore: 1972-86. Bull World Health Organ. 1988;66:57-63.
32. Scholtissek C. Source for influenza pandemics. Eur J Epidemiol. 1994;10:455-8.
33. Chew FT, Doraisingham S, Ling AE, Kumarasinghe G, Lee BW. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect. 1998;121:121-8.
34. Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science Ltd; 1998. p. 181-206.
35. Chik KW, Li CK, Chan PKS, Shing MMK, Lee V, Tam JSL, et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J. 2004;10:103-6.
36. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother. 2001;45:2723-32.
37. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4:107-16.